A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Gillian A. Horne, Jon Stobo, Caroline Kelly, Arunima Mukhopadhyay, Ayşe Latif, Judith Dixon-Hughes, Lynn McMahon, Pascale Cony‐Makhoul, Jenny Byrne, Graeme Smith, Steffen Koschmieder, Tim H. Brümmendorf, Philippe Schafhausen, Paolo Gallipoli, Fiona Thomson, Wenjuan Cong, Richard E. Clark, Dragana Milojković, G. Vignir Helgason, Letizia Foroni, Franck E. Nicolini, Tessa L. Holyoake, Mhairi Copland
Topics & Concepts
ImatinibChronic myeloid leukaemiaHydroxychloroquineMedicineInternal medicineOncologyDiseaseMyeloid leukemiaImatinib mesylateClinical trialMinimal residual diseaseLeukemiaCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia Research